11 Best Small-Cap Growth Stocks to Buy Right Now

Page 6 of 10

5. Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Market Capitalization: $1.693 billion

Analyst Upside Potential: 127.45%

Number of Hedge Fund Holders: 29

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the Best Small-Cap Growth Stocks to Buy Right Now. On August 12,  Sam Slutsky from LifeSci Capital maintained a Buy rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX) with a price target of $74.

The analyst noted that the company has shown progress in its pipeline. It is advancing its Barzolvolimab program, focusing on treating chronic spontaneous urticaria. The Phase 3 trials for this study are expected to finish enrollment in summer 2026. Moreover, the recent Phase 2 study showed promising results with many patients achieving complete responses and good disease control. Slutsky noted that the company has managed its cash burn efficiently and has a clear strategy, which justifies the Buy rating.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a clinical-stage biotech company focused on developing antibody-based therapies. The company targets mast cell-related diseases, including severe inflammatory and allergic conditions.

Page 6 of 10